Market Overview

Why AnaptysBio's Stock Is Trading Higher Today

Why AnaptysBio's Stock Is Trading Higher Today

AnaptysBio (NASDAQ: ANAB) shares are trading higher on Wednesday after Guggenheim upgraded the stock from Neutral to Buy and announced a price target of $36 per share.

AnaptysBio is a clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from collaborative research and development arrangements.

AnaptysBio shares traded up 28.77% to $22.87 on Wednesday. The stock has a 52-week high of $39.48 and a 52-week low of $10.

Latest Ratings for ANAB

Oct 2020WedbushUpgradesNeutralOutperform
Oct 2020GuggenheimUpgradesNeutralBuy
May 2020Credit SuisseMaintainsNeutral

View More Analyst Ratings for ANAB
View the Latest Analyst Ratings


Related Articles (ANAB)

View Comments and Join the Discussion!

Posted-In: why it's movingUpgrades Analyst Ratings

Latest Ratings

PMTB of A SecuritiesMaintains18.5
IVRB of A SecuritiesMaintains3.0
EFCB of A SecuritiesMaintains15.5
NYMTB of A SecuritiesMaintains3.5
NLYB of A SecuritiesMaintains8.5
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at